Skip to main content

Supracervical Hysterectomy at Sacrocolpopexy

Supracervical (subtotal) hysterectomy removes the uterine corpus and retains the cervix. At sacrocolpopexy, the retained cervix provides an attachment site without creating a vaginal cuff. This is distinct from hysteropexy, which preserves the uterus. Ovarian conservation is a separate decision.

Both supracervical and total hysterectomy are options when hysterectomy accompanies sacrocolpopexy. Some studies associate cervical preservation with fewer mesh complications, but large contemporary cohorts have produced differing results. For primary uterovaginal prolapse undergoing minimally invasive sacrocolpopexy, a 2026 global consensus recommends total vaginal or total laparoscopic hysterectomy over supracervical hysterectomy when lower composite failure is the priority, and supracervical hysterectomy over total laparoscopic hysterectomy when lower vaginal mesh exposure is the priority; both statements have moderate-quality support.[13] Choose the operation using uterine and cervical findings, the patient's preferences, the extraction plan and the accompanying prolapse repair.[1][2][3][4]

Selection and Counseling​

  • Confirm that the patient wants hysterectomy as part of repair; discuss an appropriate uterine-preserving option when there is no separate indication for hysterectomy. See Principles of Prolapse Repair.
  • Review uterine symptoms, cervical history, examination and cervical screening status. Investigate abnormal uterine or postmenopausal bleeding and suspicious findings before choosing a benign hysterectomy or tissue-fragmentation plan.
  • Explain that the cervix remains and screening follows the patient's age, history and applicable guidelines. A universal requirement for both a new normal cytology result and a negative HPV result is inappropriate.
  • Discuss ongoing cyclic bleeding and possible later cervical treatment. A 2026 meta-analysis of benign-hysterectomy trials found no established bowel or sexual-function benefit from cervical retention; an aggregate urinary-incontinence analysis beyond one year favored total hysterectomy (RR 0.67, 95% CI 0.49–0.93), but one-year, two-year sensitivity, and incontinence-subtype analyses did not show that difference.[11]

When cervical preservation is unsuitable​

  • Known or suspected uterine or cervical malignancy requires an appropriate oncologic plan rather than routine supracervical hysterectomy.
  • Significant cervical disease, a history requiring specialist surveillance, unresolved bleeding, or inability to maintain indicated follow-up may favor another approach. Current high-grade squamous cervical pathology (CIN 2/3) requires management under cervical-pathology guidance before prolapse surgery. Biopsy-proven adenocarcinoma in situ requires diagnostic excision to exclude invasion before definitive surgery; after excision, hysterectomy is preferred when fertility preservation is not needed, so routine cervical retention is unsuitable.[12] A prior CIN 3 diagnosis or a LEEP margin positive for CIN 2+ warrants review of current surveillance and recurrence risk before retaining the cervix; these findings can weigh against retention but do not by themselves make total hysterectomy the preferred prolapse operation. If total hysterectomy is selected after treatment of CIN 2/3, indicated HPV-based surveillance continues for at least 25 years after treatment despite cervical removal.[12] If cervical removal is indicated or chosen after this assessment, total hysterectomy with native-tissue apical suspension (uterosacral ligament suspension or sacrospinous ligament fixation) or sacrocolpopexy after total hysterectomy are options, weighing the mesh-exposure tradeoff from the comparative evidence above.[7][12] Do not equate every remote low-grade screening abnormality with a permanent contraindication.
  • Respect a preference for cervical removal after discussing the alternatives and their risks.[5][6]

Technique​

Laparoscopic or robotic hysterectomy usually uses the same access as the planned sacrocolpopexy. The main decisions are:

  1. Adnexal management. Discuss opportunistic salpingectomy and decide on ovarian conservation separately, according to age, risk and preferences; see Opportunistic Adnexal Surgery.
  2. Safe dissection and vascular control. Establish the bladder and ureteral relationships before dividing pedicles or amputating the corpus. Adapt dissection to adhesions, uterine size and prior surgery.
  3. Cervical stump. Preserve suitable cervical tissue for the intended repair and confirm hemostasis.[5] Endocervical treatment varies by technique; a fixed-depth thermal ablation recipe is not established by the comparative evidence.[5] Some authors recommend removing a thin disc from the exposed stump for frozen-section or histologic assessment before closure.[8]
  4. Specimen extraction. Agree on the extraction route and any tissue fragmentation before surgery. Uncontained manual fragmentation may also disperse occult malignant tissue; discuss a contained extraction method if fragmentation is needed, recognizing that outcome evidence for manual containment is limited.[14][15] Use the FDA restrictions below when considering laparoscopic power morcellation.[6]
  5. Complete the prolapse repair. Cervical retention does not replace adequate anterior and posterior vaginal support. Mesh dissection, fixation, sacral attachment, tension and peritoneal coverage belong to the Sacrocolpopexy technique. Avoid unintended vaginal penetration and bowel contact; adhesions and bowel obstruction remain possible after peritoneal coverage.

Power morcellation​

Laparoscopic power morcellation remains an option for selected patients. The FDA recommends using a compatible, legally marketed containment system when power morcellation is appropriate. Do not use it with known or suspected malignancy; for presumed fibroids, do not use it in postmenopausal patients, those over 50, or patients suitable for intact vaginal or mini-laparotomy extraction. Discuss occult malignancy and alternatives. Containment reduces tissue dispersal but cannot eliminate every route of cancer spread.[6]

Comparative Evidence at Sacrocolpopexy​

The following studies measured different outcomes. Mesh exposure on examination, a coded mesh complication and reoperation for a mesh complication are not interchangeable.

StudyPopulation and endpointFinding and interpretation
Nassif 2022 systematic review19 studies; 10,572 women undergoing sacrocolpopexy with hysterectomy; mesh erosionLower odds with supracervical hysterectomy: pooled OR 0.26 (95% CI 0.18–0.38). Reported median point prevalences were 0.36% vs 3.8%.[1]
Dallas 2022 California cohort12,189 minimally invasive sacrocolpopexies, including 3,371 concomitant supracervical and 5,027 total hysterectomies; mesh-complication reoperation0.7% vs 3.1%, with mean follow-up around three years; adjusted OR for total hysterectomy 4.20 (95% CI 2.72–6.50).[2]
Kikuchi 2023 MarketScan cohort3,463 women with at least two years of follow-up; coded complications and reoperationsNo significant difference between supracervical and total hysterectomy in mesh complications (1.8% vs 1.5%) or prolapse reoperation (1.5% vs 1.1%). Subsequent cervical procedures occurred in 0.9% of the supracervical group.[3]
Glass Clark 2024 Premier cohort17,111 minimally invasive sacrocolpopexies with hysterectomy; coded mesh exposure over two yearsExposure was 47/6,708 (0.70%) vs 65/10,403 (0.62%), without a significant difference. Prolapse reoperation was 1.4% in both groups.[4]

In a separate 733-procedure analysis comparing a prospective total-hysterectomy cohort with a retrospective supracervical cohort, unadjusted composite recurrence was 3.3% versus 4.7% (P = .40), while adjusted odds favored total hysterectomy (OR 0.21, 95% CI 0.05–0.82). Median follow-up was 369 versus 190 days, and retreatment and reoperation did not differ.[10] Hysterectomy type, surgical route and the choice between mesh and native-tissue support should be discussed as separate decisions.

Post-Operative Considerations​

  • Cervical screening. Continue when indicated for a patient with a cervix, and apply screening and surveillance criteria to the individual history. See Cervical Cancer Screening.
  • Bleeding. Recurrent or persistent bleeding needs assessment; do not automatically attribute new or postmenopausal bleeding to a benign stump. In the benign-hysterectomy Cochrane review, ongoing cyclic bleeding was more frequent after subtotal hysterectomy; its absolute frequency varied across trials.[5]
  • Symptoms and support. Assess bulge, urinary, bowel and sexual symptoms along with the examination. Cervix retention has not been shown to reliably improve these functional outcomes over total hysterectomy.[5]
  • Later cervical procedures. These may be needed for bleeding or cervical disease; consider the existing mesh attachment when planning further surgery.[3] For a later vaginal cervical-stump excision, one described sequence mobilizes the bladder anteriorly and frees the rectum and cul-de-sac posteriorly before clamping and ligating the lower cardinal and uterosacral pedicles, with the vagina and ureters swept cranially from the lateral cervix; the stump is then removed and the pedicles incorporated into the vaginal angles before transverse closure. Peritoneal entry is described as optional but preferred when complete removal or a prolapse repair with cul-de-sac obliteration or vault suspension is also planned. Attribute this sequence to its chapter authors; no comparative outcome data are reported.[9]

See Also​

Videos​

Live Supracervical Hysterectomy and Sacrocolpopexy
StitchKit by Origami Surgical (2021)

References​

1. Nassif J, Yadav GS, Orejuela FJ, Turrentine MA. Rate of mesh erosion after sacrocolpopexy with concurrent supracervical compared with total hysterectomy: a systematic review and meta-analysis. Obstet Gynecol. 2022;140(3):412-420. doi:10.1097/AOG.0000000000004901.

2. Dallas K, Taich L, Kuhlmann P, et al. Supracervical hysterectomy is protective against mesh complications after minimally invasive abdominal sacrocolpopexy: a population-based cohort study of 12,189 patients. J Urol. 2022;207(3):669-676. doi:10.1097/JU.0000000000002262.

3. Kikuchi JY, Yanek LR, Handa VL, et al. Prolapse and mesh reoperations following sacrocolpopexy: comparing supracervical hysterectomy, total hysterectomy, and no hysterectomy. Int Urogynecol J. 2023;34(1):135-145. doi:10.1007/s00192-022-05263-w.

4. Glass Clark S, Bretschneider CE, Bradley MS, et al. Risk of postoperative mesh exposure following sacrocolpopexy with supracervical versus total concomitant laparoscopic hysterectomy. Int Urogynecol J. 2024;35(1):207-213. doi:10.1007/s00192-023-05658-3.

5. Lethaby A, Mukhopadhyay A, Naik R. Total versus subtotal hysterectomy for benign gynaecological conditions. Cochrane Database Syst Rev. 2012;(4):CD004993. doi:10.1002/14651858.CD004993.pub3.

6. US Food and Drug Administration. UPDATE: Perform only contained morcellation when laparoscopic power morcellation is appropriate: FDA safety communication. December 29, 2020. FDA guidance.

7. Chang OH, Carter Ramirez A, Edwards A, et al. The role of uterine preservation at the time of pelvic organ prolapse surgery. Urogynecology (Phila). 2025;31(5):482-495. doi:10.1097/SPV.0000000000001667. AUGS Clinical Practice Statement.

8. Baggish MS. Abdominal Hysterectomy. In: Baggish MS, Karram MM, eds. Atlas of Pelvic Anatomy and Gynecologic Surgery. 5th ed. Elsevier; 2021:231-264.

9. Karram MM, Baggish MS. Cervical Stump Excision (Trachelectomy). In: Baggish MS, Karram MM, eds. Atlas of Pelvic Anatomy and Gynecologic Surgery. 5th ed. Elsevier; 2021:557-563.

10. Giugale LE, Ruppert KM, Muluk SL, et al. "Minimally Invasive Total Versus Supracervical Hysterectomy With Sacrocolpopexy." Urogynecology (Phila). 2024;30(10):814-820. doi:10.1097/SPV.0000000000001530

11. Bonavina G, Bonitta G, Puzzi E, et al. "Total Versus Sub-Total Hysterectomy: A Meta-Analysis of Randomized Controlled Trials." J Minim Invasive Gynecol. 2026;33(8):1086-1099. doi:10.1016/j.jmig.2026.03.028

12. Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis. 2020;24(2):102–131. doi:10.1097/LGT.0000000000000525.

13. Gupta A, Grimes CL, Badlani G, et al. "A Global Consensus Conference on Surgical Management of Primary Uterovaginal Prolapse and Lower Urinary Tract Dysfunction: Combining Evidence with Expert Opinion." Int Urogynecol J. Published online July 2, 2026. doi:10.1007/s00192-026-06758-6

14. American College of Obstetricians and Gynecologists. "Uterine Morcellation for Presumed Leiomyomas: ACOG Committee Opinion, Number 822." Obstet Gynecol. 2021;137(3):e63-e74. doi:10.1097/AOG.0000000000004291

15. Marcelle S, Nisolle M, Delbecque K, Goffin F, De Landsheere L. "Occult endometrial pathologies diagnosed after sacrocolpopexy with concomitant supracervical hysterectomy for pelvic organ prolapse." Front Surg. 2026;13:1704824. doi:10.3389/fsurg.2026.1704824